Metabolomics Market: Global Industry Analysis and Forecast (2021-2027) by Technology, Product, Application, Specimen, and Region

By 2027, the Metabolomics Market is expected to reach 17.00 billion. The Metabolomics instrument is one of the segments studied in the report dominating the Metabolomics market.

Metabolomics Market Overview:

Metabolomics is the systematic study of chemical processes in cell metabolism that involve metabolites, small molecule substrates, intermediates, and products. Metabolomics is the "systematic study of the distinctive chemical fingerprints left behind by specific biological processes," or the study of their small-molecule metabolite profiles. The metabolome refers to the entire range of metabolites produced by cellular processes in a biological cell, tissue, organ, or organism. The set of gene products created in the cell is revealed by messenger RNA (mRNA), gene expression data, and proteomic analysis, data that reflects one element of cellular activity. Metabolomics is a fast-growing area that combines sophisticated analytical techniques for identifying and quantifying cellular metabolites with statistical and multivariant methods for information extraction and data interpretation. In the recent two decades, tremendous progress has been achieved in the sequencing of a variety of organisms. Simultaneously, significant resources were invested in developing analytical methods for analyzing various cell products, such as gene expression (transcripts), proteins, and metabolites. All of these so-called 'omics methods, such as genomics, transcriptomics, proteomics, and metabolomics, are thought to be crucial tools for understanding an organism's biology and response to environmental stimuli or genetic disruption. Metabolomics Market To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2026. 2020 is considered a base year however 2020's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done well in lockdown also and specific strategic analysis of those companies is done in the report.

Metabolomics Market Dynamics:

Availability of government and commercial financing for metabolomics research is a driving force. Metabolomic studies are gaining traction in the life sciences industry since they can show the optimal level of certain metabolites linked to illness onset/progression, as well as treatment exposure and response. With the rising frequency and mortality rates of life-threatening diseases such as cancer and cardiovascular disease (CVD), researchers are focusing more on creative approaches that can provide better diagnosis and therapy. Additional study is being undertaken on this subject since metabolomics is considered a revolutionary method with significant potential. In addition, metabolomic indicators have become more important in medication development in recent years and this element is projected to lift the growth of the Metabolomic market. Metabolomics: an evolving but powerful tool for precision medicine Metabolomics, or the inclusive examination of metabolites in a biological material, is a new technology that has the potential to revolutionize precision medicine. Small quantities of metabolites have traditionally been utilized to detect complex metabolic diseases as well as monogenic disorders such as inborn metabolic abnormalities. Current metabolomic methods are capable of meticulous analysis of hundreds to thousands of metabolites, much exceeding the scope of typical clinical chemistry procedures. As a result, metabolomics enables detailed phenotyping of metabolic phenotypes and can enable precision medicine on a variety of levels, including the identification of metabolic instabilities that reinforce disease, the discovery of new therapeutic targets, and the identification of biomarkers that can be used to diagnose a disease or monitor therapeutic activity. hence, advancement in the field of biomarkers and technologies is likely to lift the growth of the Metabolomics market. Identifying biomarkers for clinical use: (Challenge) The delayed development in discovering which metabolites may serve as potentially useful biomarkers is a fundamental restriction of metabolomics as an emerging healthcare technology. The dynamic nature of metabolism, which can be significantly altered by genetic variances and environmental exposures, makes this more difficult. Furthermore, clinical validation by regulatory agencies is essential before a metabolic test may be used in clinical practice to verify whether it is sensitive enough to identify those at risk or affected by a disease and specific enough to a specific disease process. Hence, time-consuming clinical trials and validations processes are likely to create obstacles in the Metabolomics market.

Key Developments-

• Agilent and Thermo Fisher extended their collaboration in 2020 to expand Thermo Fisher's analytical systems' compatibility with Agilent's OpenLAb Chromatography Data System. • Hitachi purchased the remaining shares of Hitachi High-Technologies billion in 2020 and renamed it Hitachi High-Technologies. This business will be in charge of developing chipmaking equipment, as well as industrial materials and systems, as well as producing measurement and analytical equipment.

Metabolomics Market Segment Analysis:

The metabolomics instrument segment is supplementing the growth of the Metabolomics Market. In 2020, the metabolomics instrument category is predicted to command the biggest proportion of the market. The growth of this segment is expected to be fueled by factors such as technological advancements in analytical instruments in terms of miniaturization, automation, and computerization; an increase in the number of research-related activities worldwide in the fields of medicine, nutraceuticals, and metabolomics; and the strengthening of healthcare infrastructure in developing countries for efficient disease diagnosis and treatment. The biomarker discovery segment accounted for the largest share of the metabolomics market Biomarker discovery- Metabolomics is also used in Biomarker discovery for decision making. A biomarker, for example, is a chemical that is consistently present in illness samples but not in healthy people. Urine, saliva, bile, and seminal fluid samples offer a wealth of highly informative compounds that may be easily studied using metabolomics fingerprinting or profiling for biomarker development. In addition, in 2020, biomarker discovery is predicted to have the principal market share. The use of metabolic biomarkers to determine a patient's pathophysiological health condition is on the rise. Metabolomics has been a critical technique in the discovery of biomarkers in recent years as a result of considerable technological improvements. The cancer segment is anticipated to adhere to the growth of the Metabolomics Market. In 2020, the cancer segment is predicted to have the largest market share and the fastest growth rate. This is mostly due to a growth in the number of cancer patients and, as a result, an increase in the demand for cancer medicines. Further, Currently, metabolomics research is being used to find diagnostic cancer biomarkers in the clinic, better comprehend its complicated heterogeneous nature, discover cancer pathways that could be exploited for new targets, and monitor metabolic biomarkers during therapeutic intervention. These metabolomics technologies may also provide information to clinicians regarding a cancer patient's reaction to medical therapies, which could lead to customized cancer treatments. The academic and research institutes segment is estimated to grab larger market attention in the Metabolomics Market. The academic and research institutes segment accounted for the largest share of the metabolomics market in 2020. The increasing number of research activities in the field of metabolomics and funding to the academic and research institutes to conduct metabolomics research are the factors responsible for the largest share of the segment Metabolomics Market

Metabolomics Market Regional Insights:

North America is dominating the growth of the regional market in the forecast period. Throughout the projection period, North America is predicted to dominate the worldwide metabolomics market (in terms of market share). High product commercialization rates, as well as advanced healthcare-related research and development projects, are some of the causes contributing to the company's huge market share. In terms of market share, Europe is behind North America. In terms of growth rate, the Asia-Pacific metabolomics market, on the other hand, will outperform both of these areas (CAGR). One of the most significant growth contributors to this market is the rising demand for enhanced pharmaceutical products from emerging economies such as India and China. The objective of the report is to present a comprehensive analysis of the Metabolomics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Metabolomics Market dynamics, structure by analyzing the market segments and projecting the Metabolomics Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Metabolomics Market make the report investor’s guide.

Metabolomics Market Scope: Inquire before buying

Metabolomics Market

Metabolomics Market, by Region

• North America o US o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Sweden o CIS Countries o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest of Asia Pacific • The Middle East and Africa o South Africa o GCC Countries o Egypt o Nigeria o Rest of ME&A • South America o Brazil o Argentina o Rest of South America

Metabolomics Market Key Players

Waters Corporation (US) • Agilent Technologies (US) • Shimadzu Corporation (Japan) • Thermo Fisher Scientific (US) • Danaher Corporation (US) • Bruker Corporation (US) • PerkinElmer (US) • Merck KGaA (Germany) • GE Healthcare (US) • Hitachi High-Technologies Corporation (Japan) • Human Metabolome Technologies, Inc. (Japan) • LECO Corporation (US) • Metabolon, Inc. (US) • Bio-Rad Laboatories (US) • Scion Instruments (US) • DANI Instruments S.p.A. (Italy) • GL Sciences (Japan) • SRI Instruments (US) • Kore Technology Ltd. (UK) • JASCO, Inc. (US).

FAQs:

1. What is the Metabolomics market value in 2020? Ans: The Metabolomics market value in 2020 was estimated as 9.36 Billion USD. 2. Which Application is likely to dominate the Metabolomics market growth? Ans: Application-wise, the biomarker discovery segment is accounted for the largest market share in 2019. The use of metabolic biomarkers to assess the pathophysiological health status of patients is increasing. In recent years, as a result of significant technological advancements, metabolomics has become a vital tool in discovering biomarkers. 3. Which Region is expected to dominate the Metabolomics market during the forecast period? Ans: In 2020, North America dominated the Metabolomics market and accounted for the largest revenue share of 51.2%. 4. What are the factors driving the Metabolomics market? Ans: Key factors that are driving the Metabolomics market growth include rising cancer prevalence, increasing technological advancement, and government funding. 5. Who are the key players in the Metabolomics market? Ans: The major market players include the metabolomics market is dominated by a few globally established players such as Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific (US), Danaher Corporation (US), Bruker Corporation (US), PerkinElmer (US), Merck KGaA (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan).
1. Global Metabolomics Market: Research Methodology 2. Global Metabolomics Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Metabolomics Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Metabolomics Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Metabolomics Market Segmentation 4.1 Global Metabolomics Market, by Product and Services (2020-2027) • Metabolomics Instruments o Separation Tool o Detection Tool • Bioinformatics Tools and Service 4.2 Global Metabolomics Market, by Indication (2020-2027) • Cancer • Cardiovascular Disorders • Neurological Disorders • Metabolic Disorders • Inborn Errors of Metabolism • Other Indications 4.3 Global Metabolomics Market, by Application (2020-2027) • Biomarker discovery • Drug discovery • Toxicology testing • Nutrigenomics • Functional Genomics • Personalized medicine • Other Applications 4.4 Global Metabolomics Market, by End-user (2020-2027) • Academic and Research Institutes • Pharmaceutical & Biotechnology Companies • Contract Research Organizations • Other End Users 5. North America Metabolomics Market (2020-2027) 5.1 North America Metabolomics Market, by Product and Services (2020-2027) • Metabolomics Instruments o Separation Tool o Detection Tool • Bioinformatics Tools and Service 4.2 North America Metabolomics Market, by Indication (2020-2027) • Cancer • Cardiovascular Disorders • Neurological Disorders • Metabolic Disorders • Inborn Errors of Metabolism • Other Indications 4.3 North America Metabolomics Market, by Application (2020-2027) • Biomarker discovery • Drug discovery • Toxicology testing • Nutrigenomics • Functional Genomics • Personalized medicine • Other Applications 4.4 North America Metabolomics Market, by End-user (2020-2027) • Academic and Research Institutes • Pharmaceutical & Biotechnology Companies • Contract Research Organizations • Other End Users 6. Asia Pacific Metabolomics Market (2020-2027) 6.1. Asia Pacific Metabolomics Market, by Product and Services (2020-2027) 6.2. Asia Pacific Metabolomics Market, by Indication (2020-2027) 6.3. Asia Pacific Metabolomics Market, by Application (2020-2027) 6.4. Asia Pacific Metabolomics Market, by End-user (2020-2027) 6.5. Asia Pacific Metabolomics Market, by Country (2020-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Metabolomics Market (2020-2027) 7. 1 Middle East and Africa Metabolomics Market, by Product and Services (2020-2027) 7.2. Middle East and Africa Metabolomics Market, by Indication (2020-2027) 7.3. Middle East and Africa Metabolomics Market, by Application (2020-2027) 7.4. Middle East and Africa Metabolomics Market, by End-user (2020-2027) 7.5. Middle East and Africa Metabolomics Market, by Country (2020-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Metabolomics Market (2020-2027) 8.1. Latin America Metabolomics Market, by Product and Services (2020-2027) 8.2. Latin America Metabolomics Market, by Indication (2020-2027) 8.3. Latin America Metabolomics Market, by Application (2020-2027) 8.4. Latin America Metabolomics Market, by End-user (2020-2027) 8.5. Latin America Metabolomics Market, by Country (2020-2027) • Brazil • Argentina • Rest Of Latin America 9. European Metabolomics Market (2020-2027) 9.1. European Metabolomics Market, by Product and Services (2020-2027) 9.2. European Metabolomics Market, by Indication (2020-2027) 9.36. European Metabolomics Market, by Application (2020-2027) 9.4. European Metabolomics Market, by End-user (2020-2027) 9.5. European Metabolomics Market, by Country (2020-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest of Europe 10. Company Profile: Key players 10.1.1. Stemcell 10.1.1.1. Company Overview 10.1.1.2. Financial Overview 10.1.1.3. Geographic Footprint 10.1.1.4. Grade Portfolio 10.1.1.5. Business Strategy 10.1.1.6. Recent Developments 10.1.2. Waters Corporation (US) 10.1.3. Agilent Technologies (US) 10.1.4. Shimadzu Corporation (Japan) 10.1.5. Thermo Fisher Scientific (US) 10.1.6. Danaher Corporation (US) 10.1.7. Bruker Corporation (US) 10.1.8. PerkinElmer (US) 10.1.9. Merck KGaA (Germany) 10.1.10. GE Healthcare (US) 10.1.11. Hitachi High-Technologies Corporation (Japan) 10.1.12. Human Metabolome Technologies, Inc. (Japan) 10.1.13. LECO Corporation (US) 10.1.14. Metabolon, Inc. (US) 10.1.15. Bio-Rad Laboatories (US) 10.1.16. Scion Instruments (US) 10.1.17. DANI Instruments S.p.A. (Italy) 10.1.18. GL Sciences (Japan) 10.1.19. SRI Instruments (US) 10.1.20. Kore Technology Ltd. (UK) 10.1.21. JASCO, Inc. (US)

About This Report

Report ID 125700
Category Healthcare
Published Date Oct 2021
Updated Date
Contact Us